Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
Research Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (2566.HK) on Bullrun: market cap HKD 1.25B, P/E 8.2, dividend yield 1.2%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker2566.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 1.25B
- P/E8.2
- Dividend yield1.2%
- Financial periodFY2025
- RevenueCNY 1.31B
- Revenue growth-4.6%
- Net incomeCNY 138.41M
- Free cash flowCNY 150.19M
- Gross margin80.7%
Valuation Snapshot
latest market cap is HKD 1.25B; P/E is 8.2; dividend yield is 1.2%.
Peer valuation comparison
Latest P/E is 8.17x versus a Healthcare sector median of 21.69x (62.3% below).
Latest dividend yield is 1.15% versus a Healthcare sector median of 2.41% (52.3% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 1.31B | CNY 138.41M | CNY 150.19M | 80.7% | n/a | CNY 348.67M | CNY 161.62M | CNY 1.65B |
| FY2024 | CNY 1.37B | CNY 138.60M | CNY 14.94M | 79.0% | 0.68 | CNY 537.63M | CNY 120.72M | CNY 1.52B |
| FY2023 | CNY 1.29B | CNY 119.78M | CNY 88.78M | 77.0% | 0.49 | CNY 93.18M | CNY 167.07M | CNY 897.89M |
| FY2022 | CNY 1.13B | CNY 59.87M | -CNY 36.39M | 75.9% | 0.24 | CNY 71.54M | CNY 220.58M | CNY 766.18M |
| FY2021 | n/a | n/a | n/a | n/a | 0.49 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 1.25B | 8.2 | 1.3% | 0.07 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.07 HKD, yield 1.2%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.06 CNY |
About Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.'s market cap?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.'s market capitalization is HKD 1.25B.
What is Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.'s P/E ratio?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.'s price-to-earnings (P/E) ratio is 8.2.
Does Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. pay a dividend?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. has a dividend yield of 1.2%.
What does Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. do?
Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd., a biopharmaceutical company, engages in the research, development, manufacturing, and commercialization of biopharmaceutical products and medical devices in Mainland China and internationally. The company offers Guyoudao, a bone repair material; Jilifen, a human granulocyte colony stimulating factor injection; Jijufen, a human interleukin-11 injection; Jiouting, a palonosetron hydrochloride injection; Jifuwei, a fulvestrant injection; Jitansu, a fosaprepitant dimeglumine injection; and Jixinfen, PEG-GCSF injection.